Avacta Collaborating With Bruker to Evaluate MALDI-Based SARS-CoV-2 Test

Jan 28, 2021

|

NEW YORK — Biotech firm Avacta said on Thursday that it has entered into a collaboration agreement with Bruker to evaluate a MALDI mass spectrometry-based test for SARS-CoV-2 using the Avacta's Affirmer affinity reagents.

The companies will determine the test's suitability as an in vitro diagnostic for SARS-CoV-2 to be run on Bruker's MALDI-TOF instruments in the UK and Europe.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Avacta Collaborating With Bruker to Evaluate MALDI-Based SARS-CoV-2 Test

To read the full story....

Breaking News

FDA Grants Emergency Use Authorization for University of Illinois Coronavirus PCR Test

OraSure Technologies Q4 Revenues Rise 27 Percent, Beat Analysts' Estimate

CMS Releases New Guidance Requiring Payors to Cover COVID-19 Testing Without Cost Sharing

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

What's Popular?

UPDATED: Quidel At-Home, Rapid Antigen, COVID-19 Test Gets FDA Emergency Use Authorization

Roche SARS-CoV-2 Antigen Test Nabs German Approval for At-Home Self-Testing

Reference Labs Take Diverse Approaches to Mitigating COVID-19 Sample Shipping Delays

Labs, Vendors Anticipate COVID-19 Vaccines to Boost Serology Testing Demand

LightDeck Sketches Commercial Plans for Five-Minute Multiplex Tests For SARS-CoV-2, Other Conditions

Sponsorships